Dosing typically begins at a lower dose, suggested initiation of 20 units (0.2 mL) weekly for the first 4 weeks, then escalates according to a titration schedule: Weeks 14: Inject 20 units (0.2 mL) one time per week Weeks 58: Inject 40 units (0.4 mL) one time per week Weeks 912: Inject 70 units (0.7 mL) one time per week Weeks 1316: Inject 90 units (0.9 mL) one time per week Weeks 1720: Inject 120 units (1.2 mL) one time per week Week 21+: Inject 140 units (1.4 mL) one time per week Dosing may deviate from this pattern to accommodate patient-specific needs
Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer
Gentle Efficacy: The ability to achieve results without irritation means consistent, long-term use is more feasible, leading to better outcomes over time
Endocytic uptake of FITC-albumin by human alveolar epithelial cell line A549
However, studies suggest that having both eGFR creat and eGFR cysC can improve the risk prediction for end-stage kidney disease [21]
C., Reginster, J.-Y., & Bierma-Zeinstra, S